论文部分内容阅读
目的探讨血管内皮细胞生长因子(VEGF)和透明质酸酶在侵袭性垂体腺瘤中的表达及其意义。方法 2004年1月至2010年12月收集手术切除垂体腺瘤标本70例,其中侵袭性垂体腺瘤36例,非侵袭性垂体腺瘤34例,另收集12例正常脑组织标本作为对照。应用免疫组化法检测标本中VEGF蛋白质表达,用逆转录聚合酶链式反应检测标本中VEGF和透明质酸酶基因PH-20 mRNA表达,用酶联免疫吸附法测定标本中透明质酸酶活性。结果在侵袭性垂体腺瘤中VEGF蛋白质和mRNA、透明质酸酶活性及其基因PH-20 mRNA的表达水平分别为(2.52±0.32)分、1.72±0.23、(10.99±3.79)mU/g和1.60±0.28,在非侵袭性垂体腺瘤中分别为(1.56±0.68)分、0.97±0.50、(4.29±1.86)mU/g和0.41±0.19,在正常脑组织中则分别为(0.11±0.09)分、0.08±0.04、(4.10±1.96)mU/g和0.00±0.00。在侵袭性垂体腺瘤组织中VEGF蛋白质和mRNA、透明质酸酶活性及其基因PH-20 mRNA表达均显著高于在非侵袭性垂体腺瘤中的表达(P<0.05),而在非侵袭性垂体腺瘤中的表达又明显高于在正常脑组织中的表达(P<0.05)。结论 VEGF、透明质酸酶与垂体腺瘤的侵袭性密切相关,对侵袭性垂体腺瘤的诊断及预后判断有重要价值。
Objective To investigate the expression of vascular endothelial growth factor (VEGF) and hyaluronidase in invasive pituitary adenomas and its significance. Methods Seventy surgical specimens of pituitary adenomas were collected from January 2004 to December 2010. Among them, 36 were invasive pituitary adenomas and 34 were non-invasive pituitary adenomas. Twelve normal brain tissues were collected as controls. Immunohistochemistry was used to detect the expression of VEGF protein in specimens. The expression of VEGF and hyaluronidase gene PH-20 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR). The hyaluronidase activity . Results The expressions of VEGF protein, mRNA, hyaluronidase and PH-20 mRNA in invasive pituitary adenomas were (2.52 ± 0.32), 1.72 ± 0.23 (10.99 ± 3.79) mU / g and 1.60 ± 0.28, respectively (1.56 ± 0.68), 0.97 ± 0.50, (4.29 ± 1.86) mU / g and 0.41 ± 0.19 in noninvasive pituitary adenomas, respectively (0.11 ± 0.09 ), 0.08 ± 0.04, (4.10 ± 1.96) mU / g, and 0.00 ± 0.00. The expression of VEGF protein, mRNA, hyaluronidase and PH-20 mRNA in invasive pituitary adenomas were significantly higher than those in non-invasive pituitary adenomas (P <0.05) The expression of pituitary adenomas was significantly higher than that in normal brain tissues (P <0.05). Conclusion VEGF and hyaluronidase are closely related to the invasiveness of pituitary adenomas and have important value in the diagnosis and prognosis of invasive pituitary adenomas.